Related Experiment Video
Updated: Jan 16, 2026

Measuring Frailty in HIV-infected Individuals. Identification of Frail Patients is the First Step to Amelioration and Reversal of Frailty
Published on: July 24, 2013
Changes in Frailty Categorization Over One Year among Real-World Patients With Multiple Myeloma: A Prospective Cohort
Imran Haider1, Darryl P Leong2, Omar Shahid3
1Royal College of Surgeons in Ireland, Dublin, Ireland.
Background:
While the distribution of frailty status in patients with multiple myeloma (MM) has been documented at a single time point, there is limited data examining how frailty changes over time in this population.
Patients And Methods:
Patients aged > 18 years initiating treatment for newly diagnosed or relapsed MM between Aug 2021 and Jul 2023 across 3 sites in Ontario, Canada were enrolled. Frailty assessments were conducted at two time points (baseline and 12-months) using 4 frailty categorization tools: 1) the IMWG frailty index, 2) the Simplified frailty index, 3) the Mayo frailty index, and 4) the Fried frailty phenotype. At baseline and the 12-month follow-up, the frequency and proportion of patients were calculated for both frailty categorization (i.e., non-frail, frail) and continuous frailty scores (i.e., scores 0-5).
Results:
A total of 116 patients with newly diagnosed or relapsed MM were evaluated for frailty assessments at baseline and after a 12-month follow-up, using 4 different frailty indices. Changes in frailty status across the cohort varied from 13.8% to 37.1%, due to differences in how frailty was defined between each frailty index. In comparison, changes in continuous frailty score across the cohort varied from 20.7% to 51.7%. A total of 17.2% of patients experienced a reduction in gait speed of at least 0.1 m/s.
Conclusion:
This study demonstrates the dynamic nature of frailty highlighting that a one-time baseline frailty measurement may not be adequate. Additionally, continuous frailty scores may be more sensitive to early improvements/deteriorations in frailty that may go undetected using categorical frailty assessments.
Related Concept Videos
Pharmacodynamics in Geriatric Patients: Effects of Age
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
Drug Dosing: Geriatric Patients
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Cancer Survival Analysis

